Search all medical codes

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

HCPCS code

Name of the Procedure:

Injection of fosnetupitant and palonosetron (J1454).

Summary

This procedure involves the administration of a combined injection containing fosnetupitant (235 mg) and palonosetron (0.25 mg). It is typically given to prevent nausea and vomiting caused by chemotherapy.

Purpose

The injection is used to:

  • Prevent acute and delayed nausea and vomiting caused by cancer treatments such as chemotherapy.
  • Improve patient comfort and adherence to treatment by controlling one of the most distressing side effects of chemotherapy.

Indications

  • Patients undergoing moderately to highly emetogenic (nausea and vomiting inducing) chemotherapy.
  • Patients who have experienced nausea and vomiting with previous chemotherapy cycles.

Preparation

  • Patients may be advised to fast for 6-8 hours prior to the procedure.
  • It is important to review and possibly adjust concurrent medications to avoid interactions.
  • Baseline blood tests might be required to ensure the patient is fit for treatment.

Procedure Description

  1. Pre-administration: The healthcare provider will confirm the patient’s identity, review medical history, and explain the procedure.
  2. Injection Site Preparation: The injection site, typically the upper arm or thigh, will be cleaned with an antiseptic.
  3. Injection: Using a sterile technique, the combined fosnetupitant and palonosetron solution is administered intraveneously.
  4. Post-administration: The site is monitored for any immediate adverse reactions, and dressing may be applied if necessary.

Duration

The injection process typically takes about 15-30 minutes, including preparation and post-administration observation.

Setting

The procedure is usually performed in an outpatient clinic, hospital, or chemotherapy center.

Personnel

  • The injection is administered by a registered nurse or a healthcare professional trained in chemotherapy administration.
  • A physician or oncologist oversees the process and is available for any complications.

Risks and Complications

  • Common risks: Mild pain or swelling at the injection site, headache, fatigue, or constipation.
  • Rare risks: Allergic reactions, significant dizziness, or anaphylactic shock.
  • Management: Most side effects are managed with over-the-counter medication or supportive care. Severe reactions require immediate medical intervention.

Benefits

  • Effective control of nausea and vomiting associated with chemotherapy, allowing patients to maintain better nutrition and fluid intake.
  • Improved quality of life and ability to continue with scheduled chemotherapy treatments.

Recovery

  • Patients can usually go home shortly after the injection if no complications arise.
  • It’s recommended to stay hydrated and avoid heavy meals for a few hours.
  • Follow-up appointments may be scheduled to monitor the patient's response to the treatment.

Alternatives

  • Alternative medications include ondansetron, granisetron, and dexamethasone, which can also prevent chemotherapy-induced nausea and vomiting.
  • Pros: Different drugs may be more suitable for certain patients based on their medical history and specific side-effect profiles.
  • Cons: Alternatives might not be as effective in controlling delayed nausea and vomiting, and some have their own side effects.

Patient Experience

  • During the procedure, patients may feel a brief sting or mild discomfort at the injection site.
  • Post-procedure, patients may experience minor side effects such as headache or fatigue, which typically resolve within 24-48 hours.
  • Pain management might include over-the-counter pain relievers if necessary, and comfort measures such as rest and hydration are encouraged.

By adhering to this structured approach, patients can expect a reliable and effective prevention of chemotherapy-induced nausea and vomiting, enhancing their overall treatment experience.

Medical Policies and Guidelines for Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Related policies from health plans

Similar Codes